Walleye Trading
NBIX icon

Walleye Trading’s Neurocrine Biosciences NBIX Stock Holding History

Walleye Trading’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.05M Buy
8,000
+7,900
+7,900% +$1.05M ﹤0.01% 2128
2025
Q4 		$14.2K Buy
+100
New +$14.5K ﹤0.01% 4140
2024
Q4 		– Sell
-2,600
Closed -$300K – 4519
2024
Q3 		$300K Buy
+2,600
New +$356K ﹤0.01% 2839
2024
Q2 		– Sell
-7,500
Closed -$1.03M – 4704
2024
Q1 		$1.03M Buy
7,500
+6,400
+582% +$874K ﹤0.01% 2221
2023
Q4 		$145K Buy
+1,100
New +$127K ﹤0.01% 3966
2023
Q1 		– Sell
-2,200
Closed -$263K – 5196
2022
Q4 		$263K Buy
+2,200
New +$258K ﹤0.01% 3359
2022
Q1 		– Sell
-3,900
Closed -$332K – 5702
2021
Q4 		$332K Buy
3,900
+400
+11% +$36.8K ﹤0.01% 3395
2021
Q3 		$336K Buy
3,500
+2,100
+150% +$198K ﹤0.01% 3356
2021
Q2 		$136K Sell
1,400
-8,200
-85% -$786K ﹤0.01% 4214
2021
Q1 		$934K Buy
9,600
+6,700
+231% +$703K ﹤0.01% 1975
2020
Q4 		$278K Sell
2,900
-26,600
-90% -$2.57M ﹤0.01% 3215
2020
Q3 		$2.84M Buy
29,500
+4,200
+17% +$486K 0.02% 900
2020
Q2 		$3.09M Sell
25,300
-13,300
-34% -$1.47M 0.02% 799
2020
Q1 		$3.34M Buy
38,600
+4,700
+14% +$460K 0.03% 562
2019
Q4 		$3.64M Buy
33,900
+15,000
+79% +$1.57M 0.03% 779
2019
Q3 		$1.7M Sell
18,900
-25,100
-57% -$2.35M 0.01% 1183
2019
Q2 		$3.71M Buy
44,000
+20,800
+90% +$1.71M 0.03% 632
2019
Q1 		$2.04M Sell
23,200
-3,600
-13% -$301K 0.02% 1055
2018
Q4 		$1.91M Buy
26,800
+17,400
+185% +$1.67M 0.01% 1104
2018
Q3 		$1.16M Buy
9,400
+4,100
+77% +$465K 0.01% 1921
2018
Q2 		$521K Buy
+5,300
New +$474K ﹤0.01% 2806
2017
Q1 		– Sell
-100
Closed -$4K – 4997
2016
Q4 		$4K Buy
+100
New +$4.53K ﹤0.01% 4490

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Trading's NBIX Position: Q1 2026 in Review

Walleye Trading increased its Neurocrine Biosciences (NBIX) stake by 239% in Q1 2026, buying an estimated $159K and bringing the position to 1,697 shares worth $224K. The position accounts for ﹤0.01% of the portfolio, ranked #3056.

Walleye Trading first reported a position in NBIX in Q2 2015 and has held it in 19 quarters since. The position peaked at $2.79M in Q1 2020. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Walleye Trading held 1,697 shares of Neurocrine Biosciences worth $224K as of Q1 2026.
  • Walleye Trading bought 1,197 Neurocrine Biosciences shares in Q1 2026, an estimated $159K.
  • Neurocrine Biosciences made up ﹤0.01% of Walleye Trading's portfolio in Q1 2026, its #3056 holding.
  • Walleye Trading first reported a position in Neurocrine Biosciences in Q2 2015 and has held it in 19 quarters since.
  • Walleye Trading's Neurocrine Biosciences position peaked at $2.79M in Q1 2020.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.